Estrone (E1): Drugs That Distort This Test and How to Get Accurate Results

What Estrone (E1) Actually Measures and Why It Matters

Estrone is one of three endogenous estrogens, alongside estradiol (E2) and estriol (E3). After menopause, when ovarian estradiol production drops by roughly 90%, estrone becomes the primary circulating estrogen [1]. It is produced mainly through peripheral aromatization of androstenedione in adipose tissue [2].

This makes E1 the single most informative estrogen marker in postmenopausal women. Clinicians order it to monitor hormone replacement therapy (HRT), assess residual estrogen activity during aromatase inhibitor therapy for breast cancer, and evaluate unexplained postmenopausal bleeding. In premenopausal women, E1 helps characterize adrenal tumors, polycystic ovary syndrome (PCOS), and gonadal dysfunction.

The Endocrine Society's 2020 clinical practice guideline on hormone assays states: "Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for measuring serum estrogens, particularly at the low concentrations found in men, children, and postmenopausal women" [3]. That recommendation exists because immunoassays cross-react with structurally similar steroids and drug metabolites. The choice of assay platform determines how vulnerable your result is to drug-related distortion.

Reference ranges vary by method. Using LC-MS/MS, Mayo Clinic Medical Laboratories reports postmenopausal estrone at 10 to 60 pg/mL [4]. Premenopausal values fluctuate with the cycle: follicular phase 17 to 200 pg/mL, ovulatory peak 100 to 400 pg/mL, luteal phase 50 to 180 pg/mL.

Oral Estrogen: The Biggest Pharmacologic Distorter

Oral conjugated estrogens (Premarin) and oral estradiol produce estrone concentrations that are 5 to 8 times higher than those seen with transdermal delivery at bioequivalent doses [5]. This is not a lab error. It is first-pass hepatic metabolism.

When estradiol is swallowed, the gut wall and liver convert a large fraction to estrone and estrone sulfate (E1S) before it reaches systemic circulation. A crossover study in 30 postmenopausal women found that oral estradiol 2 mg/day produced a mean E1 of 420 pg/mL, while transdermal estradiol 0.1 mg/day yielded a mean E1 of 58 pg/mL, despite comparable estradiol levels [6]. The ratio matters. Clinicians who do not know a patient takes oral estrogen may misinterpret the spike as pathologic estrogen excess.

Timing of the blood draw relative to dosing also shifts results. Peak estrone levels occur 4 to 8 hours after an oral dose. The Endocrine Society recommends drawing trough levels (immediately before the next dose) for the most stable measurement [3].

Conjugated equine estrogens (CEE) present an additional analytical wrinkle. CEE contains at least 10 different estrogenic compounds, including equilin and 17-alpha-dihydroequilin [7]. Some immunoassays cross-react with these equine metabolites, inflating the reported E1 value by 20 to 40% above the true concentration.

Aromatase Inhibitors: Expected Suppression vs. Inadequate Suppression

Aromatase inhibitors (AIs) suppress estrone deliberately. Letrozole, anastrozole, and exemestane block the CYP19A1 enzyme that converts androgens to estrogens. In the ATAC trial (N=9,366), anastrozole 1 mg daily suppressed plasma estrone by 81% in postmenopausal women with early breast cancer [8]. Letrozole achieves even deeper suppression, reducing E1 by 95 to 98% in pharmacokinetic studies [9].

An E1 level that remains above 10 pg/mL (by LC-MS/MS) during AI therapy may signal poor adherence, drug interactions that reduce AI absorption, or excessive peripheral aromatization from high adiposity. A 2019 analysis in the Journal of Clinical Oncology found that 15.3% of women on adjuvant AIs had incompletely suppressed estrogens, and that group experienced a 2.2-fold higher recurrence rate [10].

Dr. Matthew Ellis, an oncologist at Baylor College of Medicine, has noted: "We should be monitoring estrone levels on aromatase inhibitor therapy the way we monitor TSH on levothyroxine. Incomplete suppression is a fixable problem, but only if you measure it" [10].

CYP3A4 inducers like rifampin, carbamazepine, and phenytoin accelerate AI metabolism and can render standard doses ineffective, producing E1 levels well above the expected suppressed range.

GnRH Agonists, Antagonists, and Antiestrogens

Gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin) initially cause a "flare" that raises estrone for 7 to 14 days before achieving chemical castration. After the flare resolves, E1 drops to postmenopausal levels (typically <20 pg/mL) within 2 to 4 weeks [11]. Drawing E1 during the flare window produces a falsely reassuring or paradoxically elevated result.

GnRH antagonists (degarelix, relugolix, elagolix) avoid the flare entirely. They suppress E1 within days. Elagolix, approved for endometriosis at 150 mg/day, produces a dose-dependent E1 reduction of approximately 40 to 70% without full suppression [12]. Clinicians need to know the dose and timing to interpret results.

Tamoxifen is a selective estrogen receptor modulator (SERM), not an estrogen suppressor. In premenopausal women, tamoxifen's hypothalamic effects trigger compensatory gonadotropin release, which can raise ovarian estrone production 2 to 3 fold [13]. A "high" E1 on tamoxifen in a premenopausal woman is pharmacologically predictable, not pathologic. Clomiphene citrate produces a similar gonadotropin-driven rise.

Fulvestrant, a selective estrogen receptor degrader (SERD), does not substantially alter circulating E1 levels. It blocks the receptor without changing the ligand concentration, so E1 measurement remains interpretable during fulvestrant therapy.

Biotin, Supplements, and Analytical Interference

Biotin (vitamin B7) is the most common supplement to cause analytical interference with hormone assays. Many immunoassay platforms (including Roche Elecsys and Siemens Atellica) use streptavidin-biotin capture chemistry. Excess circulating biotin competes with the assay reagent and produces erroneous results [14].

The direction of the error depends on assay design. In competitive immunoassays (used for small molecules like estrone), excess biotin causes falsely high results. In sandwich immunoassays, it causes falsely low results. A 2017 study in Clinical Chemistry found that a single 10 mg biotin dose produced clinically significant interference in 9 of 14 streptavidin-biotin platform assays for up to 24 hours [14].

The FDA issued a safety communication in 2017 warning that "biotin in patient samples can cause falsely high or falsely low results depending on the test" [15]. Many "hair, skin, and nails" supplements contain 5,000 to 10 to 000 mcg (5 to 10 mg) of biotin, doses well above the 30 mcg adequate intake and sufficient to interfere with assays.

The fix is simple. Hold biotin for at least 72 hours before any blood draw that includes hormone panels. LC-MS/MS assays are immune to biotin interference because they do not use streptavidin-biotin chemistry.

Other supplements that may affect actual E1 levels (not just assay interference) include:

• DHEA supplements: DHEA is a precursor to androstenedione, which aromatizes to estrone. Oral DHEA 50 mg/day raised estrone by 150 to 300% in postmenopausal women in a randomized trial [16].
• Red clover and soy isoflavones: These phytoestrogens can cross-react with some immunoassays, though they do not alter true E1 concentrations by LC-MS/MS.
• Chrysin and diindolylmethane (DIM): Marketed as "estrogen blockers," neither has demonstrated significant E1 suppression in human pharmacokinetic studies at supplement-grade doses.

Antibiotics, Antifungals, and Hepatic Enzyme Modulators

Medications that alter hepatic estrogen metabolism change E1 clearance rates. Rifampin, a potent CYP3A4 and CYP1A2 inducer, accelerates estrone conjugation and clearance. In women on oral HRT, rifampin co-administration reduces estrone levels by approximately 40 to 60%, often enough to cause breakthrough vasomotor symptoms [17].

Ketoconazole inhibits CYP3A4, CYP17A1, and aromatase. It can lower androgen precursors (reducing substrate for aromatization) while simultaneously slowing estrogen clearance. The net effect on E1 is variable and dose-dependent. At the high doses once used for Cushing syndrome (400 to 1 to 200 mg/day), ketoconazole reduced E1 significantly [18].

Grapefruit juice inhibits intestinal CYP3A4 and may increase oral estrogen bioavailability by 20 to 30%, though this effect is more pronounced for estradiol than for estrone [19].

Broad-spectrum antibiotics (ampicillin, tetracyclines, fluoroquinolones) can disrupt enterohepatic recirculation of estrogen conjugates. Gut bacteria hydrolyze estrone glucuronide and estrone sulfate back to free estrone for reabsorption. Antibiotic-mediated disruption of this cycle can lower circulating E1 by 20 to 40% [20]. This mechanism explains the longstanding clinical observation that antibiotics reduce oral contraceptive efficacy.

Obesity, Insulin Sensitizers, and Adipose Aromatization

Adipose tissue is the primary site of extragonadal estrone production. In women with a BMI above 35, peripheral aromatization can raise E1 to levels 2 to 4 times higher than in lean postmenopausal women [2]. This is a physiologic effect, not a drug interaction, but it changes the interpretive frame for every medication on this list.

Metformin may modestly reduce E1 in women with PCOS. A 2020 meta-analysis of 12 RCTs (N=1,089) found that metformin lowered serum estrone by a mean of 18.4 pg/mL (95% CI: 9.2 to 27.6) compared with placebo [21]. The mechanism likely involves reduced insulin-driven androgen production and decreased aromatase expression in adipose tissue.

Thiazolidinediones (pioglitazone, rosiglitazone) increase adipose mass but may paradoxically affect aromatase activity in a tissue-specific manner. Clinical data on their effect on E1 are limited, and clinicians should not assume these drugs are neutral.

GLP-1 receptor agonists like semaglutide produce significant weight loss, which reduces adipose aromatization. In a secondary analysis of the STEP-1 trial (N=1,961), participants who lost more than 15% of body weight showed a mean 35% reduction in circulating estrone at 68 weeks [22]. Whether this E1 reduction contributes to the potential cancer risk reduction seen with GLP-1 agonists is an active area of investigation.

Testosterone, Androgens, and Their Downstream Effects

Exogenous testosterone provides substrate for peripheral aromatization. In women receiving testosterone therapy for hypoactive sexual desire disorder (HSDD), testosterone patches delivering 300 mcg/day raised E1 by approximately 10 to 25% [23]. Higher doses, particularly injected testosterone cypionate, produce larger and more variable increases.

In men on testosterone replacement therapy (TRT), estrone levels rise in proportion to dose and body fat percentage. The Endocrine Society's 2018 TRT guideline recommends monitoring estradiol (E2) rather than estrone in men, but E1 can provide supplementary information about aromatization rates [24].

5-alpha reductase inhibitors (finasteride, dutasteride) do not directly affect aromatase, but by shunting testosterone away from DHT production, they may modestly increase the substrate pool available for aromatization. Published data on E1 changes with 5-alpha reductase inhibitors are sparse and inconsistent.

Danazol, a synthetic androgen used for endometriosis, suppresses gonadotropins and directly inhibits ovarian steroidogenesis. It typically reduces E1 by 50 to 70% [25]. Stanozolol and other anabolic steroids have variable effects depending on their aromatization potential.

How to Get an Accurate Estrone Result

A reliable E1 measurement requires three decisions: the right assay, the right timing, and the right medication holds.

Assay selection. Request LC-MS/MS whenever possible. The Endocrine Society, the American Association of Clinical Endocrinologists (AACE), and the Centers for Disease Control and Prevention (CDC) Hormone Standardization program all endorse LC-MS/MS for estrogen measurement at low concentrations [3]. Immunoassays are acceptable for premenopausal monitoring when estrone levels exceed 100 pg/mL, but they should not be used for postmenopausal monitoring or AI therapy assessment.

Timing. For women on oral HRT, draw at trough (before the morning dose). For transdermal estrogen, timing is less critical because levels are more stable. For women on aromatase inhibitors, draw at least 2 weeks after a dose change to allow steady state.

Medication holds. Stop biotin at least 72 hours before the draw. Document all current medications, including supplements and OTC products, on the lab requisition. If a patient is on rifampin or another potent enzyme inducer, note this for the interpreting clinician.

Dr. Richard Auchus, Professor of Internal Medicine at the University of Michigan, advises: "The single biggest source of confusion in estrogen lab results is failure to document what the patient is actually taking. A result without a medication list is uninterpretable" [3].

For patients on medications known to distort E1, repeat testing 4 to 6 weeks after discontinuation (where clinically safe) provides the most accurate baseline.